Your search for: 'author:("Peters, Oliver")' has returned 27 results. (0.028s) Save search

Authors: Bohlken, Jens | Peters, Oliver | Kostev, Karel

Article Type: Research Article

Abstract: Background: Clinical trials have demonstrated a significant effectiveness of Ginkgo biloba therapy versus placebo in patients with dementia. Objective: The present study aims to analyze the impact of Ginkgo biloba drug prescriptions on dementia incidence in patients with mild cognitive impairment (MCI) in a real-world setting. Methods: This retrospective study was based on the IQVIA Disease Analyzer database and included patients aged 65 or older with a first diagnosis of MCI from January 2000 to December 2019. Each patient was followed for up to 20 years after MCI diagnosis until February 2021. Date of the first diagnosis of dementia or …loss to follow-up, whichever occurred first, was noted. To estimate the association between Ginkgo biloba prescriptions during the follow-up and dementia incidence, a multivariable Cox regression analysis was performed, adjusted for age, sex, health insurance, documented co-diagnoses, and prescription of cholinesterase inhibitors. Results: Overall, 24,483 MCI patients (mean age: 77.0 years, 56.3% women) were included. It was found that > 2 prescriptions of Ginkgo biloba were significantly associated with a reduced dementia incidence (HR: 0.71 (95% CI: 0.55–0.91), p  = 0.007), as compared with no Ginkgo biloba prescription. The effect of receiving > 3 Ginkgo biloba prescriptions was even stronger, with an HR of 0.64 (95% CI: 0.48–0.86), p  = 0.003), while for > 4 prescriptions the HR was 0.58 (95% CI: 0.41–0.82) (p  = 0.002). Conclusion: All-cause dementia incidence decreased with higher numbers of Ginkgo biloba prescriptions in MCI patients. Show more

Keywords: Dementia, Ginkgo biloba extract, mild cognitive impairment, outpatients

DOI: 10.3233/JAD-215348

Citation: Journal of Alzheimer's Disease, vol. 86, no. 2, pp. 703-709, 2022

Authors: Feinkohl, Insa | Schipke, Carola G. | Kruppa, Jochen | Menne, Felix | Winterer, Georg | Pischon, Tobias | Peters, Oliver

Article Type: Research Article

Abstract: Background: Collection of cerebrospinal fluid (CSF) for measurement of amyloid-β (Aβ) species is a gold standard in Alzheimer’s disease (AD) diagnosis, but has risks. Thus, establishing a low-risk blood Aβ test with high AD sensitivity and specificity is of outmost interest. Objective: We evaluated the ability of a commercially available plasma Aβ assay to distinguish AD patients from biomarker-healthy controls. Method: In a case-control design, we examined plasma samples from 44 AD patients (A + N+) and 49 controls (A–N–) from a memory clinic. AD was diagnosed using a combination of neuropsychological examination, CSF biomarker analysis and brain imaging. Total Aβ40 and …total Aβ42 in plasma were measured through enzyme-linked immunosorbent assay (ELISA) technology using ABtest40 and ABtest42 test kits (Araclon Biotech Ltd.). Receiver operating characteristic (ROC) analyses with outcome AD were performed, and sensitivity and specificity were calculated. Results: Plasma Aβ42/40 was weakly positively correlated with CSF Aβ42/40 (Spearman’s rho 0.22; p  = 0.037). Plasma Aβ42/40 alone was not able to statistically significantly distinguish between AD patients and controls (AUC 0.58; 95% CI 0.46, 0.70). At a cut-point of 0.076 maximizing sensitivity and specificity, plasma Aβ42/40 had a sensitivity of 61.2% and a specificity of 63.6%. Conclusion: In this sample, the high-throughput blood Aβ assay was not able to distinguish well between AD patients and controls. Whether or not the assay may be useful in large-scale epidemiological settings remains to be seen. Show more

Keywords: Alzheimer’s disease, amyloid, diagnosis, high-throughput assay, plasma

DOI: 10.3233/JAD-200046

Citation: Journal of Alzheimer's Disease, vol. 74, no. 4, pp. 1285-1294, 2020

Authors: Mäurer, Anja | Himmel, Gudrun | Lange, Catharina | Mathies, Franziska | Apostolova, Ivayla | Peters, Oliver | Buchert, Ralph

Article Type: Research Article

Abstract: Background: Neuropsychological testing (NPT) of geriatric inpatients can be affected by the acute illness and/or the hospitalization. Objective: To test individualized interpretation of detailed NPT for the differentiation between primary ‘neurodegenerative’ etiologies (predominantly Alzheimer’s disease) and ‘other’ etiologies (including cerebrovascular disease) of newly detected cognitive impairment in geriatric inpatients without and with delirium in remission. Methods: 96 geriatric inpatients (81.9±5.6 years, 64.6% females) with clinically uncertain cognitive impairment were included. 31.3% had delirium in remission that was not considered the primary cause of the cognitive impairment. Categorization of the most likely etiology as ‘neurodegenerative’ or ‘other’ was established retrospectively by …a study neuropsychologist based on individualized summary assessment of detailed NPT compiled in a standardized vignette. The etiological diagnosis based on FDG-PET served as gold standard (54.2% ‘neurodegenerative’, 45.8% ‘other’). Results: Individualized summary assessment by the study neuropsychologist was correct in 80 patients (83.3%, 8 false positive, 8 false negative). The impact of delirium in remission was not significant (p  = 0.237). Individualized summary assessment by an independent neuropsychologist resulted in more false positive cases (n  = 22) at the same rate of false negative cases (n  = 8). Automatic categorization with a decision tree model based on the most discriminative NPT scores was correct in 68 patients (70.8%, 14 false positive, 14 false negative). Conclusion: Individualized summary assessment of detailed NPT in the context of relevant clinical information might be useful for the etiological diagnosis of newly detected cognitive impairment in hospitalized geriatric patients, also in patients with delirium in remission, but requires task-specific expertise. Show more

Keywords: Alzheimer’s disease, delirium, dementia, etiological diagnosis, hospitalized geriatric patients, neuropsychological testing

DOI: 10.3233/JAD-221273

Citation: Journal of Alzheimer's Disease, vol. 94, no. 2, pp. 559-584, 2023

Authors: Menne, Felix | Schipke, Carola Gertrud | Klostermann, Arne | Fuentes-Casañ, Manuel | Freiesleben, Silka Dawn | Bauer, Chris | Peters, Oliver

Article Type: Research Article

Abstract: Background: Depressive symptoms often co-occur with Alzheimer’s disease (AD) and can impact neuropsychological test results. In early stages of AD, disentangling cognitive impairments due to depression from those due to neurodegeneration often poses a challenge. Objective: We aimed to identify neuropsychological tests able to detect AD-typical pathology while taking into account varying degrees of depressive symptoms. Methods: A battery of neuropsychological tests (CERAD-NP) and the Geriatric Depression Scale (GDS) were assessed, and cerebrospinal fluid (CSF) biomarkers were obtained. After stratifying patients into CSF positive or negative and into low, moderate, or high GDS score groups, sensitivity and specificity and area …under the curve (AUC) were calculated for each subtest. Results: 497 participants were included in the analyses. In patients with low GDS scores (≤10), the highest AUC (0.72) was achieved by Mini-Mental State Examination, followed by Constructional Praxis Recall and Wordlist Total Recall (AUC = 0.714, both). In patients with moderate (11–20) and high (≥21) GDS scores, Trail Making Test-B (TMT-B) revealed the highest AUCs with 0.77 and 0.82, respectively. Conclusion: Neuropsychological tests showing AD-typical pathology in participants with low GDS scores are in-line with previous results. In patients with higher GDS scores, TMT-B showed the best discrimination. This indicates the need to focus on executive function rather than on memory task results in depressed patients to explore a risk for AD. Show more

Keywords: Alzheimer’s disease, cerebrospinal fluid, depression, executive function, memory, neuropsychology

DOI: 10.3233/JAD-200710

Citation: Journal of Alzheimer's Disease, vol. 78, no. 2, pp. 819-826, 2020

Authors: Lewczuk, Piotr | Kornhuber, Johannes | Toledo, Jon B. | Trojanowski, John Q. | Knapik-Czajka, Malgorzata | Peters, Oliver | Wiltfang, Jens | Shaw, Leslie M.

Article Type: Correction

DOI: 10.3233/JAD-159006

Citation: Journal of Alzheimer's Disease, vol. 49, no. 3, pp. 887-887, 2016

Authors: Wolfsgruber, Steffen | Polcher, Alexandra | Koppara, Alexander | Kleineidam, Luca | Frölich, Lutz | Peters, Oliver | Hüll, Michael | Rüther, Eckart | Wiltfang, Jens | Maier, Wolfgang | Kornhuber, Johannes | Lewczuk, Piotr | Jessen, Frank | Wagner, Michael

Article Type: Research Article

Abstract: Background: There is very limited data on the prevalence of abnormal cerebrospinal fluid (CSF) biomarkers of Alzheimer’s disease (AD) and their predictive value for clinical progression in memory clinic patients with subjective cognitive decline (SCD). Objective: To assess the frequency of abnormal CSF biomarkers of AD and their predictive value for clinical progression in memory clinic patients with SCD in comparison to patients with mild cognitive impairment (MCI) from the same cohort. Methods: We analyzed prospective data from memory clinic patients of the German Competence Network Dementia cohort with a baseline diagnosis of SCD (n  = 82) or MCI (n  = 134), …distinguished by actuarial neuropsychological MCI criteria (“Jak-Bondi criteria”). Risk of clinical progression during 3-year follow-up was evaluated with Cox-Proportional-Hazard models. Results: Prevalence of abnormal values in CSF markers of tau-mediated neurodegeneration (67.8% versus 46.3%) but not of amyloid deposition (40.3% versus 35.4%) was significantly higher in MCI compared to SCD. The rate of incident AD dementia (26.1% versus 12.2%) was also significantly higher in MCI. In SCD, additional 22% progressed to MCI during follow-up. Combined amyloid/tau abnormality was the strongest predictor of clinical progression in both groups. Conclusion: High prevalence of biomarker abnormality and clinical progression, together with the predictive value of CSF biomarkers, in memory clinic patients with SCD support the validity and usefulness of this condition as a “pre-MCI” at risk stage of AD. Show more

Keywords: Alzheimer’s disease, cerebrospinal fluid, mild cognitive impairment, subjective cognitive decline

DOI: 10.3233/JAD-161252

Citation: Journal of Alzheimer's Disease, vol. 58, no. 3, pp. 939-950, 2017

Authors: Lange, Catharina | Suppa, Per | Pietrzyk, Uwe | Makowski, Marcus R. | Spies, Lothar | Peters, Oliver | Buchert, Ralph | for the Alzheimer’s Disease Neuroimaging Initiative

Article Type: Research Article

Abstract: The aim of this study was to evaluate the incremental benefit of biomarkers for prediction of Alzheimer’s disease dementia (ADD) in patients with mild cognitive impairment (MCI) when added stepwise in the order of their collection in clinical routine. The model started with cognitive status characterized by the ADAS-13 score. Hippocampus volume (HV), cerebrospinal fluid (CSF) phospho-tau (pTau), and the FDG t-sum score in an AD meta-region-of-interest were compared as neurodegeneration markers. CSF-Aβ1-42 was used as amyloidosis marker. The incremental prognostic benefit from these markers was assessed by stepwise Kaplan-Meier survival analysis in 402 ADNI MCI subjects. Predefined cutoffs were …used to dichotomize patients as ‘negative’ or ‘positive’ for AD characteristic alteration with respect to each marker. Among the neurodegeneration markers, CSF-pTau provided the best incremental risk stratification when added to ADAS-13. FDG PET outperformed HV only in MCI subjects with relatively preserved cognition. Adding CSF-Aβ provided further risk stratification in pTau-positive subjects, independent of their cognitive status. Stepwise integration of biomarkers allows stepwise refinement of risk estimates for MCI-to-ADD progression. Incremental benefit strongly depends on the patient’s status according to the preceding diagnostic steps. The stepwise Kaplan-Meier curves might be useful to optimize diagnostic workflow in individual patients. Show more

Keywords: Alzheimer’s disease, biomarker, cerebrospinal fluid, FDG, magnetic resonance imaging, mild cognitive impairment, neuropsychological testing, positron emission tomography, prediction, white matter hyperintensities

DOI: 10.3233/JAD-170705

Citation: Journal of Alzheimer's Disease, vol. 61, no. 1, pp. 373-388, 2018

Authors: Polcher, Alexandra | Wolfsgruber, Steffen | Peters, Oliver | Frölich, Lutz | Wiltfang, Jens | Kornhuber, Johannes | Hüll, Michael | Rüther, Eckart | Lewczuk, Piotr | Maier, Wolfgang | Jessen, Frank | Wagner, Michael

Article Type: Research Article

Abstract: Background: Consideration of many tests from different cognitive domains in defining mild cognitive impairment (MCI) is clinical routine, but guidelines for a neuropsychological operationalization of MCI are lacking. Objective: Among different operational MCI criteria, to identify those which are best in predicting either conversion to dementia, or a biomarker profile indicative for Alzheimer’s disease (AD). Methods: Memory clinic patients without dementia (N  = 558; mean age = 66; up to 3 years of follow-up; n  = 360 with baseline CSF biomarkers) were included in an observational study using most liberal criteria of cognitive impairment. Four operational definitions of MCI were retrospectively applied: 1) amnestic …MCI (CERAD word list delayed recall), 2) CERAD total score, 3) comprehensive criteria and 4) base rate corrected CERAD. We compared their accuracy in predicting incident all-cause dementia or AD dementia within three years, or a concurrent CSF Aβ42 /tau-ratio indicative of AD. Results: The four definitions overlapped considerably, classified 35–58% of the original sample as impaired and were associated with markedly increased PPVs regarding incident all-cause dementia (39–46% versus 26% of the original sample), AD dementia and AD biomarker positivity. The base rate corrected MCI definition had the highest prognostic accuracy. Conclusion: he operational criteria examined seem suitable to specify MCI in memory clinic settings, as they identify subjects at high risk of clinical progression. Depending on the neuropsychological battery in use, one or several of these criteria could help to calibrate the clinical judgment of test results, reduce false-positive decisions, and define risk-enriched groups for clinical trials. Show more

Keywords: Alzheimer’s disease, biomarker, cognition, conversion, dementia, diagnosis, DSM-5 mild NCD, mild cognitive impairment, prognosis

DOI: 10.3233/JAD-215548

Citation: Journal of Alzheimer's Disease, vol. 88, no. 4, pp. 1663-1678, 2022

Authors: Sabbagh, Marwan N. | Schäuble, Barbara | Anand, Keshav | Richards, Danielle | Murayama, Shigeo | Akatsu, Hiroyasu | Takao, Masaki | Rowe, Christopher C. | Masters, Colin L. | Barthel, Henryk | Gertz, Hermann-Josef | Peters, Oliver | Rasgon, Natalie | Jovalekic, Aleksandar | Sabri, Osama | Schulz-Schaeffer, Walter J. | Seibyl, John

Article Type: Short Communication

Abstract: Of 57 individuals diagnosed with Alzheimer’s disease (AD) in a phase III study, 13 (23%) had amyloid-β (Aβ) levels on postmortem histopathology that did not explain the dementia. Based on postmortem histopathology, a wide range of different non-AD conditions was identified, including frontotemporal dementia, hippocampal sclerosis, and dementia with Lewy bodies. Of the histopathologically Aβ negative scored cases ante-mortem Florbetaben PET scans were classified as negative for Aβ in 11 patients based on visual analysis and in all 12 quantifiable cases based on composite standardized uptake value ratios. Thus, florbetaben PET can assist physicians in the differential diagnosis of neurodegenerative …disorders by reliably excluding Aβ pathology. Show more

Keywords: Alzheimer’s disease, florbetaben PET, histopathology

DOI: 10.3233/JAD-160821

Citation: Journal of Alzheimer's Disease, vol. 56, no. 2, pp. 441-446, 2017

Authors: Barucker, Christian | Sommer, Anette | Beckmann, Georg | Eravci, Murat | Harmeier, Anja | Schipke, Carola G. | Brockschnieder, Damian | Dyrks, Thomas | Althoff, Veit | Fraser, Paul E. | Hazrati, Lili-Naz | George-Hyslop, Peter St | Breitner, John C.S. | Peters, Oliver | Multhaup, Gerhard

Article Type: Research Article

Abstract: The pathogenesis of Alzheimer's disease (AD) is characterized by the aggregation of amyloid-β (Aβ) peptides leading to deposition of senile plaques and a progressive decline of cognitive functions, which currently remains the main criterion for its diagnosis. Robust biomarkers for AD do not yet exist, although changes in the cerebrospinal fluid levels of tau and Aβ represent promising candidates in addition to brain imaging and genetic risk profiling. Although concentrations of soluble Aβ42 correlate with symptoms of AD, less is known about the biological activities of Aβ peptides which are generated from the amyloid-β protein precursor. An unbiased DNA microarray …study showed that Aβ42 , at sub-lethal concentrations, specifically increases expression of several genes in neuroblastoma cells, notably the insulin-like growth factor binding proteins 3 and 5 (IGFBP3/5), the transcription regulator inhibitor of DNA binding, and the transcription factor Lim only domain protein 4. Using qRT-PCR, we confirmed that mRNA levels of the identified candidate genes were exclusively increased by the potentially neurotoxic Aβ42 wild-type peptide, as both the less toxic Aβ40 and a non-toxic substitution peptide Aβ42 G33A did not affect mRNA levels. In vivo immunohistochemistry revealed a corresponding increase in both hippocampal and cortical IGFBP5 expression in an AD mouse model. Proteomic analyses of human AD cerebrospinal fluid displayed increased in vivo concentrations of IGFBPs. IGFBPs and transcription factors, as identified here, are modulated by soluble Aβ42 and may represent useful early biomarkers. Show more

Keywords: Alzheimer's disease, amyloid-β, CSF proteomics, gene regulation, ID1-3, IGFBP, immunohistochemistry, LMO4, transcription factors

DOI: 10.3233/JAD-141902

Citation: Journal of Alzheimer's Disease, vol. 44, no. 2, pp. 613-624, 2015